Amneal Pharmaceuticals Analyst Ratings
Truist Financial Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $12
Amneal Pharmaceuticals (AMRX) Gets a Buy From Truist Financial
J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Hold Rating, Maintains Target Price $9
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Aura Biosciences Inc (AURA) and Terns Pharmaceuticals (TERN)
Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma
Amneal Pharmaceuticals Price Target Announced at $9.00/Share by JP Morgan
Amneal Pharmaceuticals Analyst Ratings
J.P. Morgan Initiates Amneal Pharmaceuticals(AMRX.US) With Hold Rating, Announces Target Price $9
Amneal Pharmaceuticals Analyst Ratings
Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $10
Amneal Pharmaceuticals (AMRX) Gets a Buy From Barclays
Amneal Pharmaceuticals Analyst Ratings
Truist Adjusts Price Target on Amneal Pharmaceuticals to $10 From $9, Maintains Buy Rating
Amneal Pharmaceuticals (AMRX) Receives a Buy From Barclays
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Staar Surgical (STAA) and Pliant Therapeutics (PLRX)
Goldman Sachs Adjusts Amneal Pharmaceuticals Price Target to $8 From $6.25, Maintains Buy Rating
Amneal Pharmaceuticals (AMRX) Receives a Buy From Piper Sandler
Amneal Pharmaceuticals Analyst Ratings
Truist Securities Reiterates Buy on Amneal Pharmaceuticals, Raises Price Target to $9